The standard treatments for advanced stage ovarian cancer are primary debulking surgery and intensive adjuvant chemotherapy with platinum, taxane, and bevacizumab followed by maintenance therapy including bevacizumab and poly adenosine diphosphate‐ribose polymerase (PARP) inhibitor [2, 3, 4]. This evidence concerns the gene PARP1 and ovarian carcinoma.